Recently, the Mitoxantrone Injection of Kindos Pharmaceutical Co., LTD., a subsidiary of King-Friend Co., LTD., has received defection-free approval in the first round of review by the US Food and Drug Administration (FDA) and is available for marketing.

Mitoxantrone injection is used in the treatment of multiple sclerosis, advanced hormone-refractory prostate cancer and acute non-lymphocytic leukemia. The company's mitoxantrone injection project was quickly approved within the first review cycle. This is attributed to the fact that the Kindos Pharmaceutical team has always adhered to compliance and the scientific thinking that "quality stems from design". From the product development stage to commercial launch, they have consistently implemented the working philosophy of "getting things right and well the first time". The quality system and product quality have long been trusted by regulatory authorities.

Based on the continued and steady advancement of the strategy of dual filing in China and the United States and simultaneous listing in both markets, the company has also expanded product registration, strengthened business cooperation, and enhanced brand influence in other new international markets. With stable operation, it is truly meeting the high-quality clinical medication needs of patients with major diseases worldwide.